Anti-FXYD5 (clone M53)-PEG-cardiac glycoside ADC (CAT#: ADC-W-079)

This ADC product is comprised of an anti-FXYD5 monoclonal antibody (clone M53) conjugated via a PEG linker to cardiac glycoside.

Alternative Names
FXYD5; FXYD domain containing ion transport regulator 5; RIC; IWU1; KCT1; OIT2; DYSAD; HSPC113; PRO6241; FXYD domain-containing ion transport regulator 5; dysadherin; keratinocytes associated transmembrane protein 1;

Overview
This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants.

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Description
Cardiac glycosides are organic compounds containing a glycoside (sugar) that act on the contractile force of the cardiac muscle. Because of their potency in disrupting the function of the heart, most are extremely toxic. These glycosides are found as secondary metabolites in several plants, and in some insects, such as the milkweed butterflies, that consume the plants. Chemically, the aglycone [non-sugar] part of cardiac glycoside is a steroidal moiety.

For Research Use Only. NOT FOR CLINICAL USE.